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Role of lectin pathway complement
proteins and genetic variants in organ
damage and disease severity of systemic
sclerosis: a cross-sectional study
Michael Osthoff1,2*† , Veronika K. Jaeger3†, Ingmar A. F. M. Heijnen4, Marten Trendelenburg1,2, Suzana Jordan5,
Oliver Distler5 and Ulrich A. Walker3
Abstract
Background: The role of the complement system in the pathogenesis of systemic sclerosis (SSc) is controversial.
This study investigated the role of the lectin pathway of complement as a mediator of ischemia/reperfusion injury
in SSc.
Methods: This is a prospective observational cross-sectional study of 211 SSc patients and 29 patients with
Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD) at risk of developing SSc from
two outpatient clinics. Serum levels of lectin pathway proteins (FCN-2, FCN-3, MBL, and MASP-2) and eight
MBL2 and FCN2 single-nucleotide polymorphisms (SNP) were analyzed by sandwich-type immunoassays and
genotyping and examined for their association with disease manifestations.
Results: Lectin pathway protein levels and SNPs were similar between SSc and UCTD patients. FCN-2 levels were
however higher in SSc patients with present evidence of digital ulcers (mean 1.4 vs. 1.0 μg/mL, p = 0.05), pitting scars
(mean 1.3 vs. 1.0 μg/mL, p = 0.01), and puffy fingers (mean 1.2 vs. 1.0 μg/mL, p = 0.04). Similarly, higher FCN-2 levels
were observed in SSc patients with Scl-70 autoantibodies (mean 1.5 vs. 1.0 μg/mL, p = 0.001), interstitial lung disease
(mean 1.2 vs. 0.9 μg/mL, p = 0.02), and a forced vital capacity (FVC) below 80% (mean 1.4 vs. 1.0 μg/mL, p = 0.02). In
line, variant alleles in the FCN-2 SNP at position + 6359 were associated with a significantly reduced FVC and diffusion
capacity. Furthermore, patients with SSc renal crisis harbored higher MBL levels (mean 2.7 vs. 1.5 μg/mL, p = 0.04). No
other lectin pathway protein levels or polymorphisms were associated with disease manifestations, low
complement C3 and/or C4 levels, or inflammatory markers.
Conclusions: This study does not support a relevant role for several lectin pathway complement proteins in
the pathogenesis of SSc. Higher FCN-2 levels were however associated with Scl-70 autoantibody positivity,
interstitial lung involvement, and digital vasculopathy. Elevated MBL levels were associated with renal crisis.
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Background
Systemic sclerosis (SSc) is a difficult-to-treat orphan dis-
ease that is associated with a considerable morbidity and
mortality [1]. The pathophysiological processes that
underlie SSc are complex and not completely under-
stood. Vascular injury with a subsequent dysregulation
of tissue repair has been proposed as an important para-
digm [2, 3]. Dysfunctional innate and adaptive immune
responses and microvascular injury contribute to the
clinical phenotype. Endothelial cell damage and micro-
vascular dysfunction are early and important events in
the pathogenesis of SSc and drive the activation of the
immune system [4, 5]. The complement system, a com-
plex cascade of circulating and surface-bound proteins
that play an essential role in the innate immune defense,
has been implicated in certain rheumatic diseases, such
as rheumatoid arthritis and systemic lupus erythemato-
sus [6, 7], but its role in SSc is still debated. Abnormal
local complement activation has been detected in skin
biopsies of SSc patients [8], and low serum complement
levels were also part of the first European Scleroderma
Trials and Research group activity index [9]. However, in
several subsequent studies, hypocomplementemia was
not associated with SSc disease activity [10–12].
In the presence of endothelial cell damage, the lectin acti-
vation pathway of complement has a central role in ische-
mia/reperfusion (IR) injury. After binding of the pattern
recognition receptors (PRR) mannose-binding lectin
(MBL), collectin liver 1, and ficolins (FCN-1, FCN-2, and
FCN-3) to their target structures on pathogens or stressed
and dying cells, MBL-associated serine proteases (MASP)-1
and MASP-2 are activated. In addition to downstream
complement activation, MASP-1 cleaves substrates of the
kinin and coagulation system and activates endothelial cells,
thus eliciting clot formation and conveying proinflamma-
tory signaling (reviewed in [13]). Several lines of evidence
suggest that the lectin pathway aggravates IR injury not
only in experimental models but also in humans [14–16].
Removal of cell debris by PRR has also been impli-
cated in the pathogenesis of several autoimmune dis-
eases [17–19]. Three studies have recently associated
MBL, FCN-2, and FCN-3 serum concentrations with
disease severity and organ involvement in SSc [20–22].
The number of patients studied was however small, and
the results discordant to some extent. Given the central
role of the lectin pathway in IR injury and its interaction
with stressed endothelial cells and the coagulation sys-
tem, we aimed to comprehensively assess the association
of the lectin pathway of complement with organ involve-
ment and disease severity in a larger group of SSc pa-
tients. We also included a group of patients with
Raynaud’s phenomenon in undifferentiated connective
tissue disease (UCTD) at risk of developing SSc to study
an early time point in the course of the disease [23, 24].
Methods
Participants
We conducted a cross-sectional prospective study of
Raynaud’s phenomenon in undifferentiated connective
tissue disease (UCTD) at risk of developing SSc [23, 24]
and SSc patients enrolled at the University Hospitals of
Basel and Zurich as part of the European Scleroderma
Trials and Research group centers (EUSTAR) [25]. Fol-
lowing approval by the Human Research and Ethics
Committee at participating Basel and Zurich University
SSc centers, centers were required to provide informed
written consent. Since lectin pathway proteins had previ-
ously been assessed in a healthy control group compared
to SSc patients [18, 19] and because of our primary aim
to investigate organ involvement and disease severity in
SSc patients, a control group of healthy subjects was not
included in the present study.
For inclusion into the study, SSc patients were required
to fulfill the 1980 American College of Rheumatology
(ACR) [26] or the 2013 ACR/EULAR classification criteria
[27] and to be over 18 years of age. Patients were classified
into limited or diffuse SSc depending on the most severe
skin involvement during follow-up. UCTD patients were
required to suffer from Raynaud’s phenomenon (RP) in
addition to other features compatible with early SSc such
as the presence of puffy fingers, antinuclear antibodies, or
an abnormal nail fold capillaroscopy, but not to fulfill the
2013 ACR/EULAR classification criteria for SSc [24, 27].
Clinical data at the most recent visit were used for the
purpose of this study. The presence or absence of pul-
monary hypertension (PH) was recorded according to the
judgment of the SSc expert in the center including an esti-
mation of the systolic pulmonary arterial pressure > 40
mmHg on transthoracic echocardiography, or confirm-
ation by right heart catheterization. Interstitial lung dis-
ease (ILD) was defined as the presence of characteristic
abnormalities on high-resolution chest computer tomog-
raphy or X-ray, and scleroderma renal crisis was defined
as the presence of at least two of the following: new-onset
hypertension, microangiopathic anemia, and rising cre-
atinine. Digital ulcers were defined as current ulcers distal
to or at the proximal interphalangeal joint. Pitting scars
were defined as scars distal to or at the PIP joint not
thought to be due to trauma. Disease duration was calcu-
lated from the onset of the first non-Raynaud’s
phenomenon SSc symptom.
Determination of lectin protein serum concentration and
genetic variants
Quantification of MBL serum levels was performed in
duplicates by an investigator blinded to clinical data
using a mannan-binding enzyme-linked immunosorbent
assay (ELISA) as previously described [28]. Briefly,
mannan-coated microtiter plates were incubated with
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samples at 1:25 and 1:100 dilutions for 90 min at room
temperature followed by detection of bound MBL with a
biotinylated monoclonal anti-MBL antibody (HYB
131-01, BioPorto Diagnostics, Gentofte, Denmark). Sub-
sequently, plates were developed with tetramethylbenzi-
dine substrate solution (BD OptEIA, Becton Dickinson,
Switzerland) after incubation with ExtrAvidin peroxidase
conjugate (Sigma-Aldrich, Allschwil, Switzerland),
stopped with 1M H2SO4 (Sigma-Aldrich), and read im-
mediately on a plate reader. MBL concentrations were
calculated against a standard pool serum (BioPorto
Diagnostics). MBL deficiency was defined as a serum
level below 0.5 μg/mL [29]. FCN-2, FCN-3, and MASP-2
serum levels were quantified using commercially avail-
able ELISA kits (Hycult Biothech, Uden, The
Netherlands).
For genetic analyses, genomic DNA was extracted.
Four MBL2 (rs1800451, rs1800450, rs5030737, and
rs7096206) and four FCN2 (rs3124953, rs17514136,
rs17549193, and rs7851696) promoter or exon polymor-
phisms were determined by allele-specific polymerase
chain reactions (PCR) using TaqMan fluorescent probes
(TaqMan genotyping assays, Thermo Fisher Scientific,
Lausanne, Switzerland) as described elsewhere [30]. Pro-
moter and exon polymorphisms were analyzed separ-
ately and combined as haplotypes [31].
Statistical analysis
We used chi-square tests for comparisons of categorical
variables and allele frequencies (dominant model of inher-
itance, i.e., wild-type vs. hetero- and homozygous) and to
check for the Hardy–Weinberg equilibrium. Lectin path-
way protein concentrations were analyzed by means of the
Mann–Whitney U test with regards to differences in dis-
ease severity and organ involvement, then reporting me-
dian and interquartile ranges (IQR) or by means of the
Student’s t test (then reporting mean and standard devi-
ation (SD)), as appropriate. Continuous variables were
correlated with lectin pathway protein concentrations
using Pearson correlation coefficients. Haplotype frequen-
cies were analyzed by means of the expectation-maximum
algorithm. Haplotype and linkage disequilibrium analysis
was carried out with the Haploview program (version 4.2).
All other analyses were performed with Stata/IC 13.1 (Sta-
taCorp, College Station, USA).
Results
Demographic and clinical characteristics
The study population consisted of 211 patients with
established SSc and 29 UCTD patients with visits be-
tween 2005 and 2016. Of the SSc patients, 3 patients
(1%) only fulfilled the 1980 ACR criteria [26], 38 patients
(18%) only fulfilled the 2013 ACR/EULAR criteria [27],
and 170 (81%) fulfilled both criteria. The demographics
and clinical characteristics are outlined in Table 1.
Mean age (SD) was 60 (13) and 51 (14) years in SSc
and UCTD patients, respectively, and 166 (79%) and 27
(93%) were female. Characteristics of UCTD patients in-
cluded the presence of antinuclear antibodies in 27
(93%), of puffy fingers in 2 (7%), and of abnormal nail-
fold capillaroscopy in 16 (55%) of patients. SSc patients
were classified as limited and diffuse SSc subsets in 36%
and 18%, respectively, with the remaining patients fea-
turing only sclerodactily (26%) or being classified as sine
scleroderma (20%). Anti-centromere, anti-Scl-70, and
anti-RNA polymerase III antibodies were present in
45%, 29%, and 8% of SSc cases, respectively. ILD was the
most frequently encountered organ involvement (49%).
Lectin pathway proteins in UCTD patients vs. those with
established SSc
As expected, the time since Raynaud’s phenomenon (RP)
onset was significantly shorter in UCTD compared to SSc
patients (mean 8.0 years (SD 10.0) vs. 14.2 years (SD 11.7),
p = 0.007). Similarly, the prevalence of skin and other
organ involvement was lower in UCTD patients (Table 1).
MBL2 and FCN2 allele frequencies at all eight positions
were in agreement with the predicted Hardy–Weinberg
equilibrium when including all analyzed patients (data not
shown).
Serum concentrations of the lectin pathway proteins
MBL, FCN-2, FCN-3, and MASP-2 and frequency of
FCN2 and MBL2 polymorphisms did not differ between
UCTD and SSc groups. Although, MBL deficiency de-
fined as a serum concentration below 0.5 μg/mL was nu-
merically more common in UCTD patients (48.3% vs.
31.3%, p = 0.07), MBL serum concentrations (mean 1.1
vs. 1.5 μg/mL, p = 0.1) and the frequency of MBL2 poly-
morphisms were similar (data not shown). There was no
correlation of lectin pathway proteins with the time
since RP onset as well as with the speed of disease onset,
i.e., the duration between the first non-RP manifestation
of the disease and the onset of RP (data not shown).
Association of lectin pathway proteins with organ
involvement and autoantibodies in patients with
established SSc
Regarding SSc subsets, lectin pathway protein concentra-
tions and the frequency of FCN2 and MBL2 polymor-
phisms were similar. FCN-2 concentrations were
significantly higher in SSc patients with present evidence
of digital ulcers, with pitting, and with puffy fingers
(Table 2), but not with the presence of sclerodactily, tel-
angiectasia, or joint synovitis, whereas there was no asso-
ciation with other lectin pathway proteins or
polymorphisms.
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In general, the serum concentrations of lectin pathway
proteins and the presence or absence of genetic polymor-
phisms were not associated with the modified Rodnan skin
score, the EUSTAR SSc activity score [9, 32], inflammatory
markers (ESR), the presence of hypocomplementemia, or
disease duration (data not shown). Similarly, associations of
lectin pathway protein concentrations or polymorphisms
with SSc organ involvement (including pulmonary hyper-
tension, radiographic interstitial lung disease, and pericar-
dial effusion) and its surrogate measurements (including
Table 1 Characteristics of SSc patients and patients with VEDOSS
Characteristics SSc patients
(n = 211)
UCTD
(n = 29)
All patients
(n = 240)
Female, % 79 93 80
Age (years), mean (SD) 60 (13) 51 (14) 59 (14)
Caucasian race, % 97 100 97
Duration since RP onset (years), mean (SD) 14 (12) 8 (10) 13 (12)
Duration since first non-RP (years), mean (SD) 13 (11) na na
Diffuse disease, % 18 na na
Autoantibodies, %
Anti-topoisomerase I (Scl-70) 29 7
Anti-centromere 45 34
Anti-RNA polymerase III 8 3
Organ involvement,%
Esophageal symptoms 48 31 45
Pulmonary hypertension 15 0 13
Interstitial lung disease 49 0 42
Renal crisis 2 0 2
Disease activity/severity
Digital ulcers, % 12 0 10
mRSS, median (IQR) 4 (2–9) 0 (0–0) 3 (0–9)
EUSTAR SSc activity score, median (IQR) 1 (0.5–2.0) na na
FVC (% predicted), mean (SD) 98 (21) 99 (15) 98 (20)
DLCO/va (% of predicted), mean (SD) 79 (16) 94 (17) 82 (17)
DLCO/sb (% of predicted), mean (SD) 71 (19) 96 (13) 74 (20)
Abbreviations: DLCO diffusing capacity of the lung for carbon monoxide, EUSTAR European Scleroderma Trials and Research Group, FVC forced vital capacity, mRSS
modified Rodnan skin score, RP Raynaud’s phenomenon, SD standard deviation, SSc systemic sclerosis, na not applicable
Table 2 Association of ficolin-2 concentrations with SSc skin manifestations and organ involvement
Variables Present
(μg FCN-2/ml), mean (SD)
Absent
(μg FCN-2/ml), mean (SD)
p value
Skin manifestations
Digital ulcers 1.4 (1.0) 1.0 (0.7) 0.05
Pitting scars 1.3 (0.9) 1.0 (0.7) 0.01
Puffy fingers 1.2 (1.0) 1.0 (0.6) 0.04
Sclerodactily 1.1 (0.8) 1.1 (0.8) 0.9
Telangiectasia 1.1 (0.9) 1.0 (0.7) 0.7
Organ involvement
PH 0.9 (1.2) 1.0 (0.7) 0.6
ILD by radiography 1.2 (1.1) 0.9 (0.6) 0.02
FVC < 80% predicted 1.4 (1.3) 1.0 (0.7) 0.02
Renal crisis 1.4 (1.1) 1.1 (0.9) 0.5
Abbreviations: FVC forced vital capacity, ILD interstitial lung disease, PH pulmonary hypertension, SD standard deviation
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esophageal symptoms, pulmonary artery pressure, diffusion
capacity, FVC, left ventricular ejection fraction, and pro-
teinuria), or the presence of antinuclear autoantibodies
(ANA) in general and the presence of SSc-specific autoanti-
bodies in particular were absent (data not shown). There
were however three important exceptions (Table 2).
First, there were higher FCN-2 concentrations in SSc
patients harboring Scl-70 autoantibodies than in patients
who were Scl-70 autoantibody negative (mean 1.5 μg/mL
(SD 1.2) vs. 1.0 (SD 0.7), p = 0.001).
Second, FCN-2 concentrations were associated with a
radiographic diagnosis of ILD (Table 2). Additionally
FCN-2 concentrations were lower in patients with a FVC
below 80% predicted than in those with a FVC above 80%
predicted (Table 2). In line with this observation, FVC and
diffusing capacity (DLCO) were significantly lower in pa-
tients with hetero- or homozygous variant alleles in the
FCN-2 polymorphism at position + 6359 C>T
(rs17549193), which are associated with elevated FCN-2
serum concentrations [33], compared to those with the
presence of the wild-type allele (mean FVC 95% of pre-
dicted (SD 19%) vs. 101% of predicted (SD 21%), p = 0.03;
mean DLCO 67% of predicted (SD 20%) vs. 74% of pre-
dicted (SD 18%), p = 0.02).
Third, MBL concentrations were substantially higher
in five patients with scleroderma renal crisis (mean 2.7
(SD 2.1) vs. 1.5 (SD 1.3) μg/mL, p = 0.04). In line, all five
patients with renal crisis were homozygous for the
wild-type allele of the MBL2 exon1 polymorphism at
position + 54 G>A (rs18004500) and at position + 52
C>T (rs5030737), which is strongly associated with a
high MBL concentration.
Discussion
The present study examined the association of lectin path-
way complement proteins with disease activity and organ
manifestations in a large group of SSc patients and for the
first time in a small number of patients with Raynaud’s
phenomenon in UCTD at risk of developing SSc [23]. Con-
trary to our a priori hypothesis, we failed to identify any
relevant association of several lectin pathway protein levels
and FCN2 orMBL2 polymorphisms with SSc disease activ-
ity or organ involvement. There was however an exception
of potential importance, namely an association of higher
FCN-2 concentrations with the presence of Scl-70 anti-
bodies, several hallmarks of SSc vasculopathy (digital ulcers,
pitting scars and puffy fingers), and fibrotic features (com-
promise in FVC and radiographic evidence of ILD). In
addition, the presence of variant alleles in the FCN-2 poly-
morphism at position + 6359 C>T (rs17549193) was associ-
ated with a decreased FVC and a diminished diffusion
capacity compared to the presence of the wild-type allele.
This is in support of the protein measurements, as it was
shown that variant alleles at this position are associated
with higher FCN-2 concentrations [33]. As differences in
allele frequencies in the analyzed FCN2 polymorphisms
were mostly lacking (with the exception of the association
of the + 6359 polymorphism with FVC and diffusion cap-
acity), these data may at first sight be consistent with an in-
crease in FCN-2 concentrations (increased hepatic
synthesis) as a consequence of an increased SSc activity or
the progression of SSc over time. Longitudinal comparisons
with FCN-2 concentrations in SSc patients before the dis-
ease onset are however lacking. We also can formally not
exclude the possibility that high FCN-2 concentrations may
induce Scl-70 autoantibody positivity or other mechanisms
that trigger more severe SSc.
Our results are in line with a previous study of 90 SSc
patients, which reported an association of higher FCN-2
levels with the presence of ILD and a reduced FVC [21].
In patients with idiopathic pulmonary fibrosis, above
threshold levels of plasma FCN-2 were even associated
with prolonged progression-free survival [34]. Whereas
low FCN2 levels may predispose patients to pulmonary
infections and bronchiectasis [35], increased FCN2 levels
as observed in patients with ILD in the present study
may trigger or maintain a detrimental inflammatory re-
sponse to stressed endothelial cells in the lung [36] ul-
timately resulting in the development of clinically
relevant ILD. Indeed, FCN-2 was also shown to partici-
pate in the clearance of dying cells maintaining tissue
homeostatis [37] and hence may influence the induction
of autoimmunity through mechanisms of the innate im-
mune system [38]. Although complement deposition has
been detected in pulmonary, renal, and dermal vessels
[39–41], mechanistic data regarding local FCN-2 con-
centrations in the lung and their effect on endothelial
and vascular injury and fibroblast activation are however
currently lacking.
Our results complement previous studies with regards
to MBL and FCN-3, which are two other important
PRRs of the lectin pathway [21, 22]. In a study of 90
Australian SSc patients, higher MBL levels were signifi-
cantly associated with vascular dysfunction, local tissue
damage, skin involvement, and ILD [21]. With the
exception of an association of higher MBL concentra-
tions with scleroderma renal crisis, our study does not
support a significant involvement of MBL in the patho-
genesis of SSc, at least not when measured in the serum
or when assessed by genotyping. Although local comple-
ment activation has been described in scleroderma renal
crisis [42, 43], the involvement of the lectin pathway as
compared to the classical or alternative pathway has
never been investigated previously. Thus, our results
warrant confirmation in a larger set of patients with
scleroderma renal crisis.
Differences in cohort characteristics may account for
some of the observed discrepancies, as the present study
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predominately included Caucasians (97% vs. 84% vs. 0%
in previous studies [21, 22]) and a significant proportion
of sine scleroderma SSc patients (15% vs. 1% vs. 0% in
previous studies [21, 22]). SSc is a heterogeneous dis-
ease, and hence, analyses of the lectin pathway in sub-
groups based on clinical phenotype or the presence of
certain autoantibodies may be desirable but requires a
larger study.
FCN-3 serum concentrations were not associated with
any of the investigated parameters or outcomes in the
present study. Miyagawa et al. had however previously
reported significantly lower FCN-3 serum concentra-
tions in diffuse vs. limited cutaneous SSc patients, and a
trend towards a higher prevalence of ILD in SSc patients
with lower FCN-3 concentrations [20]. In line with the
function of FCN-2, clearance of apoptotic cells is also
mediated by FCN-3 [44]. Given that FCN-3 is also pro-
duced in the lungs, sufficient pulmonary FCN-3 levels
may prevent extensive local inflammation as a conse-
quence of apoptosis, and hence, lower levels may theor-
etically predispose SSc patients to interstitial lung
disease. However, data regarding pulmonary FCN-3
levels are lacking and the small cohort size (n = 48) of
the previous study and differences in ethnic background
(100% Asian vs. 97% Caucasian in the present study)
limit the significance of the observed FCN-3 results.
While the present study provides evidence for the in-
volvement of circulating FCN-2 in SSc patients, our re-
sults do not exclude a participation of other lectin
pathway proteins in the local regulation of complement
activation in SSc [45]. Indeed, the evidence regarding
the involvement of the lectin pathway in acute IR injury
is convincing in rodents [46, 47] and even in humans
[15, 48], although its importance in the setting of
chronic low-grade ischemia, atherosclerosis, and vascu-
lar damage is less well defined [30, 49]. For example,
whereas high-producing MBL2 genotypes were associ-
ated with an increased risk of future ischemic heart dis-
ease and myocardial infarction in patients with
rheumatoid arthritis [49], the opposite was true with re-
spect to the development of myocardial infarction in dia-
betic and hypercholesterolemic individuals [50]. In
addition, different pathophysiological mechanisms dom-
inate over time in SSc, and the complement system may
play a differential role depending on the disease dur-
ation. For example, microvascular dysfunction is a hall-
mark of early SSc, and the lectin pathway may
contribute to inflammation during this stage. In contrast,
the complement system may have limited impact at the
fibrotic stage of SSc. Analyses of the lectin pathway dur-
ing different disease stages are required to verify this
hypothesis.
Limitations of the present study include the post hoc
analysis of a predefined number of PRRs of the lectin
pathway and the multiple statistical comparisons investi-
gated. In addition, the sample size may curb the detec-
tion of small differences of lectin pathway proteins or
polymorphisms, especially when analyzing rare events
such as scleroderma renal crisis. The analysis of predom-
inately Caucasian patients (97%) and of only a small per-
centage of patients with diffuse SSc (18%) may limit the
generalizability of our study results.
Conclusion
In conclusion, the present study results do not indicate a
relevant role for several lectin pathway complement pro-
teins in the pathogenesis of SSc. However, our observa-
tion of higher FCN-2 levels in SSc patients with digital
vasculopathy and ILD is notable and requires validation.
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